Fig. 5From: A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbancesPercent of eyes (Baseline PD ≥ 6 mm) ≥ 5, ≥ 10, and ≥ 15 letter improvement in Mesopic Low Contrast Visual Acuity (MLCVA) by treatment groupBack to article page